Citadel Advisors
XGN icon

Citadel Advisors’s Exagen XGN Stock Holding History

Citadel Advisors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,400
Closed -$66.1K – 15397
2025
Q1 		$66.1K Buy
18,400
+12,000
+188% +$45.3K ﹤0.01% 11997
2024
Q4 		$26.2K Buy
6,400
+6,000
+1,500% +$21.6K ﹤0.01% 12987
2024
Q3 		$1.24K Buy
400
+200
+100% +$518 ﹤0.01% 13875
2024
Q2 		$364 Sell
200
-3,900
-95% -$6.6K ﹤0.01% 14009
2024
Q1 		$6.52K Buy
4,100
+3,900
+1,950% +$7.57K ﹤0.01% 13664
2023
Q4 		$398 Buy
+200
New +$346 ﹤0.01% 14043
2023
Q2 		– Sell
-7,200
Closed -$17.5K – 15344
2023
Q1 		$17.5K Buy
+7,200
New +$18.6K ﹤0.01% 13155

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Citadel Advisors's XGN Position: Q2 2026 in Review

Citadel Advisors reduced its Exagen (XGN) stake by 94% in Q2 2026, selling an estimated $816K and leaving 14,393 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12966.

Citadel Advisors first reported a position in XGN in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.28M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Citadel Advisors held 14,393 shares of Exagen worth $66.9K as of Q2 2026.
  • Citadel Advisors sold 216,722 Exagen shares in Q2 2026, an estimated $816K.
  • Exagen made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12966 holding.
  • Citadel Advisors first reported a position in Exagen in Q2 2022 and has held it in 11 quarters since.
  • Citadel Advisors's Exagen position peaked at $1.28M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.